PURPOSE: To determine the most common drug-drug interaction (DDI) pairs contributing to QTc prolongation in cardiac intensive care units (ICUs). MATERIALS AND METHODS: This retrospective evaluation included patients who were admitted to the cardiac ICUs between January 2009 and July 2009 aged ≥ 18 years with electrocardiographic evidence of a QTc ≥ 500 ms. Patients receiving at least two concomitant drugs known to prolong the QT interval were considered to experience a pharmacodynamic DDI. Drugs causing CYP450 inhibition of the metabolism of QT prolonging medications were considered to cause pharmacokinetic DDIs. The causality between drug and QTc prolongation was evaluated with an objective scale. RESULTS: One hundred eighty-seven patients experienced QT prolongation out of a total of 501 patients (37%) admitted during the study period. Forty-three percent and 47% of patients experienced 133 and 179 temporally-related pharmacodynamic and pharmacokinetic interactions, respectively. The most common medications related to these DDIs were ondansetron, amiodarone, metronidazole, and haloperidol. CONCLUSION: DDIs may be a significant cause of QT prolongation in cardiac ICUs. These data can be used to educate clinicians on safe medication use. Computerized clinical decision support could be applied to aid in the detection of these events.
PURPOSE: To determine the most common drug-drug interaction (DDI) pairs contributing to QTc prolongation in cardiac intensive care units (ICUs). MATERIALS AND METHODS: This retrospective evaluation included patients who were admitted to the cardiac ICUs between January 2009 and July 2009 aged ≥ 18 years with electrocardiographic evidence of a QTc ≥ 500 ms. Patients receiving at least two concomitant drugs known to prolong the QT interval were considered to experience a pharmacodynamic DDI. Drugs causing CYP450 inhibition of the metabolism of QT prolonging medications were considered to cause pharmacokinetic DDIs. The causality between drug and QTc prolongation was evaluated with an objective scale. RESULTS: One hundred eighty-seven patients experienced QT prolongation out of a total of 501 patients (37%) admitted during the study period. Forty-three percent and 47% of patients experienced 133 and 179 temporally-related pharmacodynamic and pharmacokinetic interactions, respectively. The most common medications related to these DDIs were ondansetron, amiodarone, metronidazole, and haloperidol. CONCLUSION:DDIs may be a significant cause of QT prolongation in cardiac ICUs. These data can be used to educate clinicians on safe medication use. Computerized clinical decision support could be applied to aid in the detection of these events.
Authors: Adrian Wong; Adam Wright; Diane L Seger; Mary G Amato; Julie M Fiskio; David Bates Journal: Appl Clin Inform Date: 2017-08-23 Impact factor: 2.342
Authors: Sharan L Campleman; Jeffery Brent; Anthony F Pizon; Joshua Shulman; Paul Wax; Alex F Manini Journal: Clin Toxicol (Phila) Date: 2020-04-07 Impact factor: 4.467
Authors: Antonio Siniscalchi; Francesco Scaglione; Enzo Sanzaro; Francesco Iemolo; Giorgio Albertini; Gianluca Quirino; Maria Teresa Manes; Santo Gratteri; Nicola Biagio Mercuri; Giovambattista De Sarro; Luca Gallelli Journal: Clin Drug Investig Date: 2014-12 Impact factor: 2.859
Authors: Mary Grace Fitzmaurice; Adrian Wong; Hannah Akerberg; Simona Avramovska; Pamela L Smithburger; Mitchell S Buckley; Sandra L Kane-Gill Journal: Drug Saf Date: 2019-09 Impact factor: 5.606